What Will Happen to Apellis Pharmaceuticals, Inc. (APLS) Next? The Stock Just Increased A Lot

March 14, 2018 - By Winifred Garcia

The stock of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a huge mover today! The stock increased 12.63% or $2.83 during the last trading session, reaching $25.23. About 191,551 shares traded or 49.93% up from the average. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 8 months positive chart setup for the $1.27 billion company. It was reported on Mar, 14 by Barchart.com. We have $26.24 PT which if reached, will make NASDAQ:APLS worth $50.80 million more.

More notable recent Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news were published by: Globenewswire.com which released: “Apellis Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare …” on January 02, 2018, also Globenewswire.com with their article: “Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) to Ring The Nasdaq Stock Market …” published on December 13, 2017, Globenewswire.com published: “Apellis Pharmaceuticals Announces Closing of its Initial Public Offering” on November 13, 2017. More interesting news about Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) were released by: Globenewswire.com and their article: “Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of …” published on February 22, 2018 as well as Seekingalpha.com‘s news article titled: “Apellis Pharmaceuticals: This Horse Is Lame” with publication date: January 09, 2018.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $1.27 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. It currently has negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: